LIVIVO - Search results -

Search results

Result 1 - 10 of total 163

Search options

Article ; Online: Which trial do we need? Infectious and non-infectious complications of peripherally inserted central venous catheters and midline catheters.

Buetti, Niccolò / Marschall, Jonas / Catho, Gaud / Timsit, Jean-François / Mermel, Leonard

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

2023 Volume 29, Issue 5, Page(s) 568–569

MeSH term(s)	Humans ; Central Venous Catheters/adverse effects ; Central Venous Catheters/microbiology ; Catheterization, Central Venous/adverse effects ; Communicable Diseases/complications ; Catheterization, Peripheral/adverse effects ; Catheter-Related Infections/microbiology ; Risk Factors ; Retrospective Studies
Language	English
Publishing date	2023-01-20
Publishing country	England
Document type	Journal Article
ZDB-ID	1328418-6
ISSN	1469-0691 ; 1470-9465 ; 1198-743X
ISSN (online)	1469-0691
ISSN	1470-9465 ; 1198-743X
DOI	10.1016/j.cmi.2023.01.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4541: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 284: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparison of clinical outcomes over time of inpatients with healthcare-associated or community-acquired coronavirus disease 2019 (COVID-19): A multicenter, prospective cohort study.

Grant, Rebecca L / Sauser, Julien / Atkinson, Andrew / D'Incau, Stéphanie / Buetti, Niccolò / Zanella, Marie-Céline / Harbarth, Stephan / Marschall, Jonas / Catho, Gaud

Infection control and hospital epidemiology

2023 Volume 45, Issue 1, Page(s) 75–81

Abstract: Objective: To compare clinical outcomes over time of inpatients with healthcare-associated coronavirus disease 2019 (HA-COVID-19) versus community-acquired COVID-19 (CA-COVID-19).: Design: We conducted a multicenter, prospective observational cohort ... ...

Abstract	Objective: To compare clinical outcomes over time of inpatients with healthcare-associated coronavirus disease 2019 (HA-COVID-19) versus community-acquired COVID-19 (CA-COVID-19). Design: We conducted a multicenter, prospective observational cohort study of inpatients with COVID-19. Setting: The study was conducted across 16 acute-care hospitals in Switzerland. Participants and methods: We compared HA-COVID-19 cases, defined as patients with a positive severe acute respiratory coronavirus virus 2 (SARS-CoV-2) test > 5 days after hospital admission, with hospitalized CA-COVID-19 cases, defined as those who tested positive within 5 days of admission. The composite primary outcome was patient transfer to an intensive care unit (ICU) or an intermediate care unit (IMCU) and/or all-cause in-hospital mortality. We used cause-specific Cox regression and Fine-Gray regression to model the time to the composite clinical outcome, adjusting for confounders and accounting for the competing event of discharge from hospital. We compared our results to those from a conventional approach using an adjusted logistic regression model where time-varying effects and competitive risk were ignored. Results: Between February 19, 2020, and December 31, 2020, we included 1,337 HA-COVID-19 cases and 9,068 CA-COVID-19 cases. HA-COVID-19 patients were significantly older: median, 80 (interquartile range [IQR], 71-87) versus median 70 (IQR, 57-80) ( Conclusions: The risk of adverse clinical outcomes for HA-COVID-19 cases increased substantially over time in hospital and exceeded that for CA-COVID-19. Using approaches that do not account for time-varying effects or competing events may not fully capture the true risk of HA-COVID-19 compared to CA-COVID-19.
MeSH term(s)	Humans ; COVID-19/epidemiology ; Prospective Studies ; SARS-CoV-2 ; Inpatients ; Retrospective Studies ; Intensive Care Units ; Hospital Mortality
Language	English
Publishing date	2023-08-02
Publishing country	United States
Document type	Observational Study ; Multicenter Study ; Journal Article
ZDB-ID	639378-0
ISSN	1559-6834 ; 0195-9417 ; 0899-823X
ISSN (online)	1559-6834
ISSN	0195-9417 ; 0899-823X
DOI	10.1017/ice.2023.143
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1714: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prevalence and significance of bacterial contamination of autologous stem cell products.

Damonti, L / Buetti, N / Droz, S / Bacher, U / Pabst, T / Taleghani, B M / Baerlocher, G M / Marschall, J

The Journal of hospital infection

2021 Volume 114, Page(s) 175–179

Abstract: There is limited and conflicting information on the prevalence of contamination of haematopoietic stem and progenitor cell products (HPCPs), and their optimal management remains unclear. The authors reviewed the microbial surveillance data of HPCPs ... ...

Abstract	There is limited and conflicting information on the prevalence of contamination of haematopoietic stem and progenitor cell products (HPCPs), and their optimal management remains unclear. The authors reviewed the microbial surveillance data of HPCPs collected between January 2002 and December 2019 for autologous transplantation at the study institution to determine the prevalence of microbial contamination and the potential infectious complications among recipients. Among 3935 HPCPs, 25 (0.6%) were contaminated. Ultimately, 22 patients received contaminated grafts, with pre-emptive antimicrobial therapy initiated in six of these patients. No patients developed subsequent infectious complications. These data suggest that microbial contamination of autologous HPCPs and associated adverse outcomes are rare.
MeSH term(s)	Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cells ; Humans ; Prevalence ; Retrospective Studies ; Transplantation, Autologous/adverse effects
Language	English
Publishing date	2021-04-15
Publishing country	England
Document type	Journal Article
ZDB-ID	779366-2
ISSN	1532-2939 ; 0195-6701
ISSN (online)	1532-2939
ISSN	0195-6701
DOI	10.1016/j.jhin.2021.04.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1586: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: PAIN2.0: study protocol for a multicentre randomised controlled trial to evaluate the efficacy of a 10-week outpatient interdisciplinary multimodal pain therapy to manage recurrent pain for patients with risk factors of developing chronic pain in Germany.

Meyer-Moock, Sandra / Szczotkowski, Daniel / Schouten, Leonie / Petzke, Frank / Milch, Lena / Metz-Oster, Beatrice / Zinndorf, Louise / Geber, Christian / Hoffmann, Greta / Preißler, Anke / Marschall, Ursula / Rottke, Felix / Waidner, Anja / Möller, André / Isenberg, Thomas / Lindena, Gabriele / Gärtner, Anne / Kaiser, Ulrike / Kohlmann, Thomas

Trials

2024 Volume 25, Issue 1, Page(s) 145

Abstract: Background: Up to 27% of the German population suffers from recurrent or persistent pain (lasting more than three months). Therefore, prevention of chronic pain is one major object of pain management interventions. The aim of this nationwide, ... ...

Abstract	Background: Up to 27% of the German population suffers from recurrent or persistent pain (lasting more than three months). Therefore, prevention of chronic pain is one major object of pain management interventions. The aim of this nationwide, multicentre, randomised controlled trial is to evaluate the efficacy of a 10-week ambulatory (outpatient) interdisciplinary multimodal pain therapy (A-IMPT) for patients with recurrent pain and at risk of developing chronic pain. This project was initiated by the German Pain Society (Deutsche Schmerzgesellschaft e.V.) and the public health insurance provider BARMER. It is currently funded by the German Innovation Fund (01NVF20023). The study PAIN2.0 focuses on reducing pain intensity and pain-related disability and investigates whether this intervention can improve physical activity, psychological well-being, and health literacy. Methods: PAIN2.0 is designed as a multicentre 1:1 randomised controlled trial with two parallel groups (randomisation at the patient level, planned N = 1094, duration of study participation 12 months, implemented by 22 health care facilities nationwide). After 6 months, patients within the control group also receive the intervention. The primary outcomes are pain intensity and pain-related impairment, measured as Characteristic Pain Intensity (PI) and Disability Score (DS) (Von Korff), as well as patient-related satisfaction with the intervention. Secondary outcomes are the number of sick leave days, sickness allowance, treatment costs, psychological distress, health-related quality of life, and catastrophizing. The effects of the intervention will be analysed by a parallel-group comparison between the intervention and control groups. In addition, the long-term effects within the intervention group will be observed and a pre-post comparison of the control group before and after the intervention will be performed. Discussion: Recurrent or persistent pain is common in the German population and causes high costs for patients and society. The A-IMPT aims to improve pain and pain-related impairments in pain patients at risk of chronification, thereby reducing the risk of developing chronic pain with its high socioeconomic burden. This new therapy could easily be integrated into existing therapy programs if positively evaluated. Trial registration: The trial PAIN2.0 has been registered in the German Clinical Trials Register (DRKS) since 21/11/2022 with the ID DRKS00030773 .
MeSH term(s)	Humans ; Chronic Pain/diagnosis ; Chronic Pain/therapy ; Outpatients ; Quality of Life ; Exercise ; Risk Factors ; Cost-Benefit Analysis ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
Language	English
Publishing date	2024-02-23
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1745-6215
ISSN (online)	1745-6215
ISSN	1468-6694 ; 1745-6215
DOI	10.1186/s13063-024-07975-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update.

Buetti, Niccolò / Marschall, Jonas / Drees, Marci / Fakih, Mohamad G / Hadaway, Lynn / Maragakis, Lisa L / Monsees, Elizabeth / Novosad, Shannon / O'Grady, Naomi P / Rupp, Mark E / Wolf, Joshua / Yokoe, Deborah / Mermel, Leonard A

Infection control and hospital epidemiology

2022 , Page(s) 1–17

Language	English
Publishing date	2022-04-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	639378-0
ISSN	1559-6834 ; 0195-9417 ; 0899-823X
ISSN (online)	1559-6834
ISSN	0195-9417 ; 0899-823X
DOI	10.1017/ice.2022.87
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1714: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Device runtime and costs of cardiac resynchronization therapy pacemakers - a health claims data analysis.

Hadwiger, Moritz / Dagres, Nikolaos / Hindricks, Gerhard / L'hoest, Helmut / Marschall, Ursula / Katalinic, Alexander / Frielitz, Fabian-Simon

German medical science : GMS e-journal

2022 Volume 20, Page(s) Doc02

Abstract: Introduction: ...

Abstract	Introduction:
MeSH term(s)	Cardiac Resynchronization Therapy ; Cardiac Resynchronization Therapy Devices ; Data Analysis ; Defibrillators, Implantable ; Humans ; Pacemaker, Artificial ; Treatment Outcome
Language	English
Publishing date	2022-03-04
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2113606-3
ISSN	1612-3174 ; 1612-3174
ISSN (online)	1612-3174
ISSN	1612-3174
DOI	10.3205/000304
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Fatty Diet Induces a Jejunal Ketogenesis Which Inhibits Local SGLT1-Based Glucose Transport via an Acetylation Mechanism-Results from a Randomized Cross-Over Study between Iso-Caloric High-Fat versus High-Carbohydrate Diets in Healthy Volunteers.

Elebring, Erik / Wallenius, Ville / Casselbrant, Anna / Docherty, Neil G / Roux, Carel W le / Marschall, Hanns-Ulrich / Fändriks, Lars

Nutrients

2022 Volume 14, Issue 9

Abstract: Background and aims: Insights into the nature of gut adaptation after different diets enhance the understanding of how food modifications can be used to treat type 2 diabetes and obesity. The aim was to understand how diets, enriched in fat or ... ...

Abstract	Background and aims: Insights into the nature of gut adaptation after different diets enhance the understanding of how food modifications can be used to treat type 2 diabetes and obesity. The aim was to understand how diets, enriched in fat or carbohydrates, affect glucose absorption in the human healthy jejunum, and what mechanisms are involved. Methods: Fifteen healthy subjects received, in randomised order and a crossover study design, two weeks of iso-caloric high-fat diet (HFD) and high-carbohydrate diet (HCD). Following each dietary period, jejunal mucosa samples were retrieved and assessed for protein expression using immunofluorescence and western blotting. Functional characterisation of epithelial glucose transport was assessed ex vivo using Ussing chambers. Regulation of SGLT1 through histone acetylation was studied in vitro in Caco-2 and human jejunal enteroid monolayer cultures. Results: HFD, compared to HCD, decreased jejunal Ussing chamber epithelial glucose transport and the expression of apical transporters for glucose (SGLT1) and fructose (GLUT5), while expression of the basolateral glucose transporter GLUT2 was increased. HFD also increased protein expression of the ketogenesis rate-limiting enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS2) and decreased the acetylation of histone 3 at lysine 9 (H3K9ac). Studies in Caco-2 and human jejunal enteroid monolayer cultures indicated a ketogenesis-induced activation of sirtuins, in turn decreasing SGLT1 expression. Conclusion: Jejunal glucose absorption is decreased by a fat-enriched diet, via a ketogenesis-induced alteration of histone acetylation responsible for the silencing of SGLT1 transcription. The work relates to a secondary outcome in ClinicalTrials.gov (NCT02088853).
MeSH term(s)	Acetylation ; Caco-2 Cells ; Cross-Over Studies ; Diabetes Mellitus, Type 2/metabolism ; Diet ; Glucose/metabolism ; Healthy Volunteers ; Histones/metabolism ; Humans ; Jejunum/metabolism ; Ketone Bodies/metabolism ; Sodium-Glucose Transporter 1/genetics ; Sodium-Glucose Transporter 1/metabolism
Chemical Substances	Histones ; Ketone Bodies ; Sodium-Glucose Transporter 1 ; Glucose (IY9XDZ35W2)
Language	English
Publishing date	2022-05-07
Publishing country	Switzerland
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2518386-2
ISSN	2072-6643 ; 2072-6643
ISSN (online)	2072-6643
ISSN	2072-6643
DOI	10.3390/nu14091961
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Letter: ileal bile acid transporter inhibition- is there a potential for drug-drug interaction? Authors' reply.

Marschall, H-U / Gillberg, P-G / Rikner, L / Graffner, H

Alimentary pharmacology & therapeutics

2016 Volume 43, Issue 6, Page(s) 751

MeSH term(s)	Female ; Humans ; Male ; Proton Pump Inhibitors/administration & dosage ; Stomach Neoplasms/epidemiology
Chemical Substances	Proton Pump Inhibitors
Language	English
Publishing date	2016-03
Publishing country	England
Document type	Comment ; Letter
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1111/apt.13543
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation.

Graffner, H / Gillberg, P-G / Rikner, L / Marschall, H-U

Alimentary pharmacology & therapeutics

2016 Volume 43, Issue 2, Page(s) 303–310

Abstract: Background: Reabsorption of bile acids from the intestine by ileal bile acid transporter is pivotal for the enterohepatic circulation of BAs and sterol homoeostasis.: Aim: To assess tolerability and study, bile acid metabolism in a phase 1 trial with ...

Abstract	Background: Reabsorption of bile acids from the intestine by ileal bile acid transporter is pivotal for the enterohepatic circulation of BAs and sterol homoeostasis. Aim: To assess tolerability and study, bile acid metabolism in a phase 1 trial with the selective ileal bile acid transporter inhibitor A4250. Methods: A randomised double-blind, single-ascending dose (SAD) and multiple-ascending-dose study consisting of five cohorts comprising 40 individuals with a single administration of A4250 (0.1, 0.3, 1, 3, or 10 mg) or placebo and three cohorts comprising 24 individuals with a 1-week administration of A4250 (1 or 3 mg once daily or 1.5 mg twice daily) or placebo. For the multiple-ascending-dose study, bile acids were measured by HPLC-MS in plasma and faeces, and fibroblast growth factor 19 (FGF19) and 7α-hydroxy-4-cholesten-3-one (C4) were measured in plasma. Results: No serious adverse events occurred and all participants finished the trial per protocol. At the end of the multiple-ascending-dose study, plasma total bile acids and FGF19 decreased by 47% and 76%, respectively, at 3 mg/day (P < 0.01), and by 15% and 16%, respectively, at 1.5 mg twice daily (P < 0.05). Plasma C4 and faecal bile acids increased at all dose regimens, by 555%, 664%, 292% and 338%, 421%, 420%, respectively (P < 0.01-0.05). The primary bile acids cholic and chenodeoxycholic acids constituted the majority of faecal bile acids in the A4250-treated groups. Conclusions: A4250 is well tolerated. By blocking ileal bile acid transporter in the terminal ileum, it highly efficiently interrupts the enterohepatic circulation of BAs, and should be of benefit to patients with cholestatic liver diseases. Clinical Trial registration EudraCT 2013-001175-21.
MeSH term(s)	Adult ; Bile Acids and Salts/metabolism ; Carrier Proteins/antagonists & inhibitors ; Chenodeoxycholic Acid/metabolism ; Cholestenones/blood ; Double-Blind Method ; Enterohepatic Circulation/drug effects ; Feces/chemistry ; Female ; Fibroblast Growth Factors/blood ; Humans ; Ileum/metabolism ; Intestines/metabolism ; Male ; Membrane Glycoproteins/antagonists & inhibitors
Chemical Substances	Bile Acids and Salts ; Carrier Proteins ; Cholestenones ; FGF19 protein, human ; Membrane Glycoproteins ; bile acid binding proteins ; Chenodeoxycholic Acid (0GEI24LG0J) ; 7 alpha-hydroxy-4-cholesten-3-one (3862-25-7) ; Fibroblast Growth Factors (62031-54-3)
Language	English
Publishing date	2016-01
Publishing country	England
Document type	Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1111/apt.13457
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study.

van Elk, Michiel / Fejer, George / Lempe, Pascal / Prochazckova, Luisa / Kuchar, Martin / Hajkova, Katerina / Marschall, Josephine

Psychopharmacology

2021 Volume 239, Issue 6, Page(s) 1705–1720

Abstract: There is an increased societal trend to engage in microdosing, in which small sub-hallucinogenic amounts of psychedelics are consumed on a regular basis. Following subjective reports that microdosing enhances the experience of nature and art, in the ... ...

Abstract	There is an increased societal trend to engage in microdosing, in which small sub-hallucinogenic amounts of psychedelics are consumed on a regular basis. Following subjective reports that microdosing enhances the experience of nature and art, in the present study we set out to study the effects of psilocybin microdosing on feelings of awe and art perception. In this preregistered combined field- and lab-based study, participants took part in a microdosing workshop after which they volunteered to self-administer a psilocybin microdose or a placebo for three consecutive weeks, while the condition was kept blind to the participants and researchers. Following a 2-week break, the condition assignment was reversed. During each block, participants visited the lab twice to measure the effects of psilocybin microdosing vs. placebo. We used standardized measures of awe, in which participants reported their experiences in response to short videos or when viewing abstract artworks from different painters. Our confirmatory analyses showed that participants felt more awe in response to videos representing funny animals and moving objects in the microdosing compared to the placebo condition. However, about two-third of our participants were breaking blind to their experimental condition. Our exploratory findings suggest that expectancy-effects may be a driving factor underlying the subjective benefits of microdosing.
MeSH term(s)	Animals ; Dose-Response Relationship, Drug ; Esthetics ; Hallucinogens/pharmacology ; Humans ; Psilocybin/pharmacology ; Surveys and Questionnaires
Chemical Substances	Hallucinogens ; Psilocybin (2RV7212BP0)
Language	English
Publishing date	2021-04-30
Publishing country	Germany
Document type	Journal Article
ZDB-ID	130601-7
ISSN	1432-2072 ; 0033-3158
ISSN (online)	1432-2072
ISSN	0033-3158
DOI	10.1007/s00213-021-05857-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui I Zs.240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito